2nd Quarter and First Half 2018 Report | Gentian
15930
post-template-default,single,single-post,postid-15930,single-format-standard,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-14.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.5.5,vc_responsive
 

2nd Quarter and First Half 2018 Report

2nd Quarter and First Half 2018 Report

Moss, 17 August 2018

Gentian Diagnostics AS announces its results for the second quarter and first half year. The highlights of the quarter include:

  • 37% revenue growth vs 1H 2017
  • fCAL turbo and CCRP with record sales in 2Q18
  • Proof of concept achieved for new pancreatic elastase assay
  • Share issue with net proceeds of MNOK 68.5

Please find the report for the second quarter and first half year enclosed. The report will also be made available on www.gentian.no.

For further information, please contact:

Bård Sundrehagen
EVP Business Development, Gentian Diagnostics
E-mail: Bard.sundrehagen@gentian.no
Cell Phone: +47 924 14 117

Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525

MeldingsID: 457417
UtstederID: GENT-ME
Instrument: GENT-ME
Marked: Merkur Market
Kategori: HALVÅRSRAPPORTER OG REVISJONSBERETNINGER / UTTALELSER OM FORENKLET REVISORKONTROLL
Informasjonspliktige opplysninger: Ja

 

Vedlegg: GDAS 2018 2Q Interim report (1)



Get in touch

Please fill out the form below.

X
CONTACT US